Fosdin Pack

Fosdin Pack

calcium citrate + vitamin d3

alendronic acid

Manufacturer:

Hersil

Distributor:

MedChoice Endocrine Group
Concise Prescribing Info
Contents
Per Weekly (round) FC tab Alendronic acid 70 mg. Per Daily (oval) tab Ca citrate 1.5 g, cholecalciferol (vit D3) 200 IU
Indications/Uses
Treatment of osteoporosis in postmenopausal women & increases bone mass in men w/ osteoporosis.
Dosage/Direction for Use
Adult Treatment of osteoporosis in postmenopausal women & to increase bone mass in men w/ osteoporosis 1 Wkly (round) tab once a wk & 1 Daily (oval) tab every day for 7 days (do not take w/ Wkly tab simultaneously).
Administration
Daily tab: Should be taken with food.. Weekly FC tab: Should be taken on an empty stomach: Take w/ a full glass of plain water at least 30 min before the 1st food/drink/medication of the day & remain in sitting/upright position for at least 30 min. Swallow whole, do not chew/dissolve in the mouth.
Contraindications
Hypersensitivity. Alendronic acid: GI diseases eg, duodenitis, dysphagia, symptomatic GERD, pyrosis, gastritis, gastroesophageal reflux, hiatal hernia & peptic ulcer. Patients w/ CrCl <35 mL/min (0.58 mL/sec). Hypocalcemia (primary or secondary) or vit D deficiency. Ca citrate & vit D3: Hypercalcemia (primary or secondary), hypercalciuria, kidney calculus; sarcoidosis; dehydration or electrolyte imbalance; chronic diarrhea or GI malabsorption; hypercalcemia; end stage renal failure; history of kidney stones; idiosyncrasy.
Special Precautions
Adverse Reactions
Abdominal pain. Rarely, unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis.
Drug Interactions
Alendronic acid: Absorption may be interfered if taken w/ food, nutritional supplements (Ca) or drugs (antacids). Doubled the bioavailability w/ IV ranitidine. Increased incidence of adverse events of the upper GIT w/ salicylate compd. Increased risk of hypoglycemia w/ aminoglycosides. Reduced absorption of Ca & Fe salts. Drugs which absorption may be modified w/ the presence of high doses of Ca. Decreased absorption w/ alcohol & caffeine intake & tobacco use. Reduced response w/ Ca-channel blockers. Reduced Ca absorption w/ high amounts of food intake w/ fiber, grains, cereals or phytates. Antagonized hypercalcemia treatment w/ calcitonin. May induce hypercalcemia w/ thiazide diuretics. Increased Ca absorption w/ estrogens. Decreases absorption of bisphosphonates. Reduced bioavailability w/ phenytoin. Reduced absorption w/ fluoroquinolones. Decreased absorption w/ Na fluoride. Diminishes the effect of cellulose Na phosphate. May increase the potential of Ca deposits in soft tissues w/ K phosphate/Na phosphate. Decreased absorption w/ Fe. Reduced Ca levels in the blood w/ gallium nitrate. Hypercalcemia or hypermagnesemia w/ Ca or Mg-containing prep. Milk-alkali syndrome w/ dairy products & Na bicarbonate. Reduced absorption w/ tetracyclines. Stimulates bone loss & counteracts the effects of Ca supplementation & may cause hypercalcemia w/ vit A (>7500 RE or >25,000 IU). Increases intestinal absorption of Ca w/ vit D, calciferol & calcitriol. Decreases from normal levels of serum phosphate.
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BB05 - alendronic acid, calcium and colecalciferol, sequential ; Belongs to the class bisphosphonates, combinations. Used in the treatment of bone diseases.
Presentation/Packing
Form
Fosdin pack
Packing/Price
1 × 8's (P365/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in